MRK vs MYGN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
MYGN exhibits severe operational distress, highlighted by a critical Piotroski F-Score of 1/9, indicating a fundamental collapse in financial health. While the balance sheet remains liquid with a strong current ratio (2.67) and low debt-to-equity (0.33), these are lagging indicators compared to the alarming -20.80% YoY revenue decline and -41.29% profit margin. The stock is in a long-term secular decline, losing over 82% of its value over five years, and current valuation is supported only by asset value (P/B 1.25) rather than earnings power.
Compare Another Pair
Related Comparisons
MRK vs MYGN: Head-to-Head Comparison
This page compares Merck & Co., Inc. (MRK) and Myriad Genetics, Inc. (MYGN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.